The study was designed to evaluate and compare the effects of co-administration of atorvastatin (10 mg) either with niacin (1 g) or fenofibrate (200 mg) daily for 12 weeks in 67 coronary heart disease patients with dyslipidemia. There were no significant differences among the two groups (35 patients in Group I and 32 patients in Group II) in serum lipid profile except in level of triglyceride reduction where fenofibrate-atorvastatin combination yielded significant (p<0.001) results. SGPT level significantly raised and fasting blood glucose level decreased in fenofibrate-atorvastatin treated group than niacin-atorvastatin combination. Serum creatinine level decreased in niacin-atorvastatin treated group compared to fenofibrate-atorvastatin, ...
Hyperlipidemia can be effectively treated either with niacin or HMG-CoA reductase inhibitor (statin)...
OBJECTIVE: To evaluate the efficacy of fenofibrate, simvastatin or their combination in type 2 diabe...
AbstractBackground:Plasma lipid abnormalities commonly persist in patients with diabetic dyslipidemi...
The study was designed to evaluate and compare the effects of co-administration of atorvastatin (10 ...
A comparative study on the effects of niacin plus atorvastatin with that of fenofibrate plus atorvas...
Objective: Statins being the first choice drug for dyslipidaemia, the quest for better one among all...
Jose G Jimenez-Montero,1 Gregory Haft2 1Post Graduate Studies, University of Medical Sciences, San J...
OBJECTIVES: Atherogenic dyslipidemia is emerging as a target of lipid-modifying therapy. However, an...
Diabetes is the most common metabolic disease. Type 2 diabetes is a variable combination of insulin ...
In the current study, the metabolic effects of atorvastatin dose escalation versus atorvastatin/feno...
Background: Cardiovascular diseases (CVDs) are the major cause of death globally. Dyslipidemia is on...
Background: Cardiovascular diseases are one of the most important group of diseases causing prematur...
ObjectivesWe compared vascular and metabolic responses (and adverse responses) to statin and fibrate...
William Insull Jr1, Peter P Toth2, H Robert Superko3, Roopal B Thakkar4, Scott Krause4, Ping Jiang4,...
Manoj Sharma1, Deepika R Sharma1, Vikram Singh1, RB Panwar2, HS Hira3, Bishav Mohan4, Naveen Kumar4,...
Hyperlipidemia can be effectively treated either with niacin or HMG-CoA reductase inhibitor (statin)...
OBJECTIVE: To evaluate the efficacy of fenofibrate, simvastatin or their combination in type 2 diabe...
AbstractBackground:Plasma lipid abnormalities commonly persist in patients with diabetic dyslipidemi...
The study was designed to evaluate and compare the effects of co-administration of atorvastatin (10 ...
A comparative study on the effects of niacin plus atorvastatin with that of fenofibrate plus atorvas...
Objective: Statins being the first choice drug for dyslipidaemia, the quest for better one among all...
Jose G Jimenez-Montero,1 Gregory Haft2 1Post Graduate Studies, University of Medical Sciences, San J...
OBJECTIVES: Atherogenic dyslipidemia is emerging as a target of lipid-modifying therapy. However, an...
Diabetes is the most common metabolic disease. Type 2 diabetes is a variable combination of insulin ...
In the current study, the metabolic effects of atorvastatin dose escalation versus atorvastatin/feno...
Background: Cardiovascular diseases (CVDs) are the major cause of death globally. Dyslipidemia is on...
Background: Cardiovascular diseases are one of the most important group of diseases causing prematur...
ObjectivesWe compared vascular and metabolic responses (and adverse responses) to statin and fibrate...
William Insull Jr1, Peter P Toth2, H Robert Superko3, Roopal B Thakkar4, Scott Krause4, Ping Jiang4,...
Manoj Sharma1, Deepika R Sharma1, Vikram Singh1, RB Panwar2, HS Hira3, Bishav Mohan4, Naveen Kumar4,...
Hyperlipidemia can be effectively treated either with niacin or HMG-CoA reductase inhibitor (statin)...
OBJECTIVE: To evaluate the efficacy of fenofibrate, simvastatin or their combination in type 2 diabe...
AbstractBackground:Plasma lipid abnormalities commonly persist in patients with diabetic dyslipidemi...